Does tumour dormancy offer a therapeutic target?
The increasing number of cancer survivors is cause for celebration, but this expanding population has highlighted the problem of tumour dormancy, which can lead to relapse. As we start to understand more about the biology of dormant cancer cells, we can begin to address how best to treat this form of disease. Preclinical models and initial clinical trials, as exemplified in patients with breast cancer, are paving the way to address how best to treat long-term cancer survivors to minimize the risk of cancer recurrence.
Harvard Medical School, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Lawrence House, RH-302, Boston, Massachusetts 02114, USA.
Paul E
PE
Goss
Ann F
AF
Chambers
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009360:Neoplastic Cells, Circulating; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D017741:Survivors
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human